Featured Press Release

  • 8/9/17 6:50 am EDT

    -- Bendeka market share of 96% --

    -- Revenue grows 22% year-over-year to $50.1 million --–

    -- Board of Directors approves additional share buyback program of $100 million --–

    -- Company enters into $150 million Amended and Restated Credit Agreement --–

    -- Implements initial expense reduction program --

    WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq:EGRX) today announced its financial results for the three and six months ended June 30, 2017. Highlights of and subsequent to the second quarter of 2017 include: Business Highlights: Bendeka® total market share of 96%, as of June 30, 2017; Sales of RYANODEX® grew 54% to $5.2 million during the second quarter of 2017 compared to $3.4more